Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB859,58601,12
PKN75,8275,9-1,32
Msft-1,75
Nokia4,7024,747-2,15
IBM-0,88
Daimler AG7171,02-1,07
PFE-1,30
18.09.2021 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 17.09.2021
Omeros (NASDAQ Cons)
Závěr k 17.9.2021 Změna (%) Změna (USD) Objem obchodů (ks)
15,98 1,40 0,22 790 316
After-hours18.09.2021 2:00:00
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
15,98 - - 1,40 0,22
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 20.09.2021
Popis společnosti
Obecné informace
Název společnostiOmeros Corporation
TickerOMER
Kmenové akcie:Ordinary Shares
RICOMER.O
ISIN-
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky30.06.2021
Počet zaměstnanců k 31.12.2020 277
Akcie v oběhu k 05.08.2021 62 495 645
MěnaUSD
Kontaktní informace
Ulice201 Elliott Ave W
MěstoSEATTLE
PSČ98119-4240
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 066 765 000
Fax12066765005

Business Summary: Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.
Financial Summary: BRIEF: For the six months ended 30 June 2021, OmerosCorporation revenues increased 35% to $49.9M. Net lossincreased 2% to $63.7M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsResearch and development - Balancing increase of 23% to$61.4M (expense), Other General and administrative increaseof 17% to $36.1M (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBusiness Services
MGSECTORServices
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 20.09.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive OfficerGregory Demopulos6215.10.2013
Vice President, Finance, Chief Accounting Officer and TreasurerMichael Jacobsen6215.10.201303.09.2013
Vice President, Science and Chief Scientific OfficerGeorge Gaitanaris64
Vice President, General Counsel, SecretaryPeter Cancelmo4210.06.201910.06.2019
Vice President, Human ResourcesPeter Williams53
Vice President - Nonclinical DevelopmentChristopher Bral55
Vice President, Chief Commercial OfficerNadia Dac51
Vice President - Chemistry, Manufacturing and ControlsBruce Meiklejohn61
Vice President - Regulatory Affairs & Quality Systems, Chief Regulatory OfficerCatherine Melfi61
Vice President - PatentsTina Quinton5801.01.2012